Entera Bio (ENTX) Change in Accured Expenses (2021 - 2026)

Entera Bio (ENTX) has 6 years of Change in Accured Expenses data on file, last reported at -$2000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 100.23% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156000.0 (down 85.3% YoY) and the FY2025 annual result came in at $1.0 million, up 414.29% from the prior year.
• Change in Accured Expenses eased to -$2000.0 in Q1 2026, from $204000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $886000.0 in Q1 2025 to a low of -$808000.0 in Q1 2022.
• A 5-year average of -$52117.6 and a median of $28000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 2106.9% — and 2025, when it surged 3064.29%.
• Tracing ENTX's Change in Accured Expenses over 5 years: stood at $581000.0 in 2022, then plunged by 213.94% to -$662000.0 in 2023, then surged by 147.13% to $312000.0 in 2024, then tumbled by 34.62% to $204000.0 in 2025, then tumbled by 100.98% to -$2000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$2000.0 (Q1 2026), $204000.0 (Q4 2025), and -$77000.0 (Q3 2025), per Business Quant data.